Literature DB >> 10385247

Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands).

J F Pregenzer1, G L Alberts, W B Im, J L Slightom, M D Ennis, R L Hoffman, N B Ghazal, R E TenBrink.   

Abstract

1. Both the 5-HT1D and 5-HT1B receptors are implicated in migraine pathophysiology. Recently isochromans have been discovered to bind primate 5-HT1D receptors with much higher affinity than 5-HT1B receptors. In the guinea-pig, a primary animal model for anti-migraine drug testing, however, isochromans bound the 5-HT1D receptor with lower affinity than the gorilla receptor. 2. This species-specific pharmacology was investigated, using site-directed mutagenesis on cloned guinea-pig receptors heterologously expressed in human embryonic kidney 293 cells. Mutations of threonine 100 and arginine 102 at the extracellular side of transmembrane II of the guinea-pig 5-HT1D receptor to the corresponding primate residues, isoleucine and histidine, respectively, enhanced its affinity for isochromans to that of the gorilla receptor, with little effects on its affinities for serotonin, sumatriptan and metergoline. Free energy change from the R102H mutation was about twice as much as that from the T100I mutation. 3. For G protein-coupling, serotonin marginally enhanced GTPgamma35S binding in membranes expressing the guinea-pig 5-HT1D receptor and its mutants, but robustly in membranes expressing the gorilla receptor. Sumatriptan enhanced GTPgamma35S binding in the latter nearly as much as serotonin, and several isochromans by 30-60% of serotonin. 4. We discovered key differences in the function and binding properties of guinea-pig and gorilla 5-HT1D receptors, and identified contributions of I100 and H102 of primate 5-HT1D receptors to isochroman binding. Among common experimental animals, only the rabbit shares I100 and H102 with primates, and could be useful for studying isochroman actions in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385247      PMCID: PMC1566017          DOI: 10.1038/sj.bjp.0702532

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology.

Authors:  H T Kao; N Adham; M A Olsen; R L Weinshank; T A Branchek; P R Hartig
Journal:  FEBS Lett       Date:  1992-08-03       Impact factor: 4.124

2.  Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater.

Authors:  W S Lee; M A Moskowitz
Journal:  Brain Res       Date:  1993-10-29       Impact factor: 3.252

3.  Characterization of the functional activity of dopamine ligands at human recombinant dopamine D4 receptors.

Authors:  C Chabert; C Cavegn; A Bernard; A Mills
Journal:  J Neurochem       Date:  1994-07       Impact factor: 5.372

Review 4.  Molecular biology of 5-HT receptors.

Authors:  F G Boess; I L Martin
Journal:  Neuropharmacology       Date:  1994 Mar-Apr       Impact factor: 5.250

5.  Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.

Authors:  I Bouchelet; Z Cohen; B Case; P Séguéla; E Hamel
Journal:  Mol Pharmacol       Date:  1996-08       Impact factor: 4.436

6.  Chimeric mutagenesis of putative G-protein coupling domains of the alpha2A-adrenergic receptor. Localization of two redundant and fully competent gi coupling domains.

Authors:  M G Eason; S B Liggett
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

7.  Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.

Authors:  G W Rebeck; K I Maynard; B T Hyman; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model.

Authors:  L Schmetterer; M Wolzt; K Krejcy; U Graselli; O Findl; H G Eichler; E A Singer
Journal:  Clin Pharmacol Ther       Date:  1996-08       Impact factor: 6.875

9.  Cloning and characterisation of the rabbit 5-HT1D alpha and 5-HT1D beta receptors.

Authors:  G Harwood; M Lockyer; H Giles; N Fairweather
Journal:  FEBS Lett       Date:  1995-12-11       Impact factor: 4.124

10.  Comparison of interactions of [3H]muscimol, t-butylbicyclophosphoro[35S]thionate, and [3H]flunitrazepam with cloned gamma-aminobutyric acidA receptors of the alpha 1 beta 2 and alpha 1 beta 2 gamma 2 subtypes.

Authors:  J F Pregenzer; W B Im; D B Carter; D R Thomsen
Journal:  Mol Pharmacol       Date:  1993-05       Impact factor: 4.436

View more
  9 in total

1.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

2.  Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.

Authors:  E Muñoz-Islas; S Gupta; L R Jiménez-Mena; J Lozano-Cuenca; A Sánchez-López; D Centurión; S Mehrotra; A MaassenVanDenBrink; C M Villalón
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

3.  Molecular cloning, sequence analysis and pharmacological properties of the porcine 5-HT(1D) receptor.

Authors:  P Bhalla; H S Sharma; T Wurch; P J Pauwels; P R Saxena
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

4.  The GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction: resemblance to the 5-HT(1B), but not to the 5-HT(1D) or 5-ht(1F), receptor subtype.

Authors:  D Centurión; A Sánchez-López; P De Vries; P R Saxena; C M Villalón
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

5.  The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.

Authors:  D J Williamson; R G Hill; S L Shepheard; R J Hargreaves
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes.

Authors:  Araceli Sánchez-López; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-12       Impact factor: 3.000

7.  Advances in drug development for acute migraine.

Authors:  Ryan J Cady; Candace L Shade; Roger K Cady
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

8.  Acute migraine therapy: new drugs and new approaches.

Authors:  Teshamae S Monteith; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

Review 9.  Post-triptan era for the treatment of acute migraine.

Authors:  Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2004-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.